07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

CAT-2054: Phase IIa data

Top-line data from a double-blind, U.S. Phase IIa trial in 153 patients with hypercholesterolemia showed that oral CAT-2054 plus atorvastatin missed the primary endpoint of reducing LDL-C from baseline to week 4 vs. placebo plus...
08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

CAT-2054: Phase IIa started

Catabasis began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 250 and 400 mg oral CAT-2054 once or twice daily with 40 mg oral atorvastatin daily for 4 weeks in about 150 patients. Catabasis...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

CAT-2054: Preliminary Phase I data

Preliminary data from a 2-part, double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 78 healthy volunteers showed that single and multiple doses of 50-1,000 mg oral CAT-2054 were well tolerated with no serious adverse events...